NLS Pharmaceutics (NLS Pharmaceutics) Equity-to-Asset : -4.78 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NLS Pharmaceutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-8.83 Mil. NLS Pharmaceutics's Total Assets for the quarter that ended in Dec. 2023 was $1.85 Mil.

The historical rank and industry rank for NLS Pharmaceutics's Equity-to-Asset or its related term are showing as below:

NLSP' s Equity-to-Asset Range Over the Past 10 Years
Min: -60.37 Med: -3.06 Max: 0.51
Current: -1.89

During the past 7 years, the highest Equity to Asset Ratio of NLS Pharmaceutics was 0.51. The lowest was -60.37. And the median was -3.06.

NLSP's Equity-to-Asset is ranked worse than
94.43% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs NLSP: -1.89

NLS Pharmaceutics Equity-to-Asset Historical Data

The historical data trend for NLS Pharmaceutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Equity-to-Asset Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-8.87

-7.41

0.09

0.35

-4.78

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial								0.09	-1.96	0.35	-1.89	-4.78

Competitive Comparison of NLS Pharmaceutics's Equity-to-Asset

For the Biotechnology subindustry, NLS Pharmaceutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Equity-to-Asset falls into.

NLS Pharmaceutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NLS Pharmaceutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-8.834	/	1.847
	=

NLS Pharmaceutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-8.834	/	1.847
	=

NLS Pharmaceutics (NAS:NLSP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

NLS Pharmaceutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.